ConCallIQ
Go Pro
DRLALPATHLABS Diversified 13 May 2026

Dr Lal Path Labs — Q4 FY26

Dr.

bullish high
Compare with...
Revenue ₹703 Cr +16.6%
EBITDA ₹187 Cr +10.5%
PAT ₹132 Cr -15.4%
EBITDA Margin 26.6% -150bps
Duration 54 min
Read Time 1 min read

✓ Verified against BSE filing

Risk Intelligence

Material risks this quarter

Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.

Risks

R

Middle East War Impact on Reagent Supply

Prolonged conflict could disrupt supply chain for imported reagents and consumables, impacting costs and availability.

medium · analyst_question
R

Margin Pressure from Investments

Continued investment in labs, R&D, and new initiatives like SOAKA may keep margins in 27-28% range, limiting near-term expansion.

medium · management_commentary
R

Price Hike Delay

Management indicated price hike is 'a few quarters away' and dependent on market conditions, delaying potential margin tailwind.

low · management_commentary